Egyptian International Pharmaceutical Investments (CAI:PHAR) Accounts Payable: E£946 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:PHAR Egyptian International Pharmaceutical Investments CAI:PHAR
71 GF Score
Price E£104.00
GF Value E£59.96
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Egyptian International Pharmaceutical Investments Accounts Payable?

Egyptian International Pharmaceutical Investments CAI:PHAR +7.77% 71 Accounts Payable is E£946 Mil as of Mar. 2026. GuruFocus rates CAI:PHAR with a GF Score™ of 71/100 and a GF Value™ of E£59.96 (Significantly Overvalued). The stock has 12 warning signs investors should review.

Egyptian International Pharmaceutical Investments's Accounts Payable for the quarter that ended in Mar. 2026 was E£946 Mil.

Egyptian International Pharmaceutical Investments's quarterly Accounts Payable declined from Jun. 2025 (E£613 Mil) to Sep. 2025 (E£456 Mil) but then increased from Sep. 2025 (E£456 Mil) to Mar. 2026 (E£946 Mil).

Egyptian International Pharmaceutical Investments's annual Accounts Payable declined from Dec. 2022 (E£200 Mil) to Dec. 2023 (E£176 Mil) but then increased from Dec. 2023 (E£176 Mil) to Dec. 2024 (E£410 Mil).

Egyptian International Pharmaceutical Investments Accounts Payable Related Terms

Egyptian International Pharmaceutical Investments Accounts Payable Historical Data

* Premium members only.

The historical data trend for Egyptian International Pharmaceutical Investments's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egyptian International Pharmaceutical Investments Accounts Payable Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 75.45 200.25 176.35 410.39

Egyptian International Pharmaceutical Investments Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 410.39 718.39 613.45 455.84 945.70
CAI:PHAR
71GF Score
Egyptian International Pharmaceutical Investments CAI:PHAR
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Egyptian International Pharmaceutical Investments Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of E£946 Mil mean?
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a Accounts Payable of E£946 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Egyptian International Pharmaceutical Investments and its competitors.
Is Egyptian International Pharmaceutical Investments' Accounts Payable too high?
Egyptian International Pharmaceutical Investments' current Accounts Payable is E£946 Mil. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' Accounts Payable compare to ZTS and UTHR?
Egyptian International Pharmaceutical Investments' Accounts Payable of E£946 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Egyptian International Pharmaceutical Investments and its competitors. Egyptian International Pharmaceutical Investments's current Accounts Payable is E£946 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.96, compared to a current price of E£104.00 — trading 73.4% above its estimated fair value. The current Accounts Payable is E£946 Mil. Egyptian International Pharmaceutical Investments' overall GF Score™ is 71/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current Accounts Payable is E£946 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued. The current stock price of E£104.00 is trading 73.4% above its estimated GF Value™ of E£59.96. GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.

Key valuation signals for CAI:PHAR:

  • Accounts Payable: E£946 Mil
  • GF Value™: E£59.96 vs. price of E£104.00 (73.4% above fair value)
  • GF Score™: 71/100 with 12 warning signs

No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Egyptian International Pharmaceutical Investments Business Description

Address 1st Industrial Zone B1, EIPICO, Tenth of Ramadan City, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
71GF Score

Get the complete analysis for CAI:PHAR

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£104.00
Price
E£59.96
GF Value